Wave Life Sciences’ Post

View organization page for Wave Life Sciences, graphic

18,204 followers

Today we announced positive results from the Phase 1b/2a SELECT-HD study with the first clinical demonstration of allele-selective mutant huntingtin lowering in #HuntingtonsDisease.      Read about these results: https://lnkd.in/emiPXzCc Join us at 8:30 a.m. ET for an investor conference call.

  • “We are very proud to have demonstrated mHTT lowering of 46%, with preservation of wtHTT, and are encouraged to see these reductions in mHTT significantly correlating with a slowing in caudate atrophy after just 28 weeks. These results represent a significant achievement for Wave, for the oligonucleotide field, and most importantly, for the HD community.”​
Joanne Kaattari

DownStreamer ➡️ Project Research & Writing ➡️ Huntington's Disease Family ➡️ Caregiver ➡️ Patient Partner ➡️ Micro Online Bookstore➡️ Labyrinth Walker ➡️ Always Literacy

3mo

A family member participated in the Precision HD clinical trial with Wave Life Sciences for 3 years. He was devastated when it failed. He knew a cure would not come in time for him, but he desperately wanted to help others in the race for a cure for Huntington's Disease. I promised him that his sacrifice mattered & good would result in future clinical trials. It's so very wonderful to learn of the success of Select HD! KB died this past winter, and it truly means a lot to know that his sacrifice did indeed matter and that this new clinical trial would have used trial data and lessons learned from Precision HD. It's a very happy day for Huntington's Disease families! Thank you Wave Life Sciences. 💕

Bernard Andruss

SVP/GM Bio-Techne Diagnostics Division

3mo

Great to see that Wave's selective targeting approach is lowering expression of the mutant HTT allele, but is correlated with indicators of clinical response. This is great news for the HD community and provides hope for affected families. Congrats to the Wave team!

Darren Nelson 🚀 (We're hiring)

Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies

3mo

Congratulations on the positive results from the Phase 1b/2a SELECT-HD study! The clinical demonstration of allele-selective mutant huntingtin lowering in Huntington's Disease is a significant milestone. 🌟 #HuntingtonsDisease #ClinicalResearch Wave Life Sciences Recruits Lab (We're hiring) BioJobs Lab

Like
Reply
Alzbeta Mühlbäck, MD, PhD

Huntington-Zentrum-Süd am kbo-Isar-Amper-Klinikum, Affiliation Klinikum rechts der Isar Technische Universität München & Deutsches Zentrum für Psychische Gesundheit (DZPG)

3mo

Congratulations and excited to hear more on the investigator conference call!

Like
Reply
Anne Van Dusen

Chief Operating Officer at Huntington Study Group

3mo

Fantastic news! What a tremendous advancement toward providing a disease modifying treatment for HD!

Brett Chinn

Professional Shaman | BCG Alum

3mo

Seth Rotberg, MNM saw this and thought of you.

Marina Papoutsi

Senior Biomarker Scientist

3mo

Congratulations to everyone 👏🎉!! What an achievement!

Zenon Raddon

Experienced Life Science Recruiter

3mo

Congrats Anne-Marie Li-Kwai-Cheung and the entire Wave Life Sciences team!

Like
Reply
Shawn Britt

Senior Patent Agent at Nimbus Therapeutics

3mo

Wow!!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics